DrugInformations.org

Results of the PRoFESS(R) (Prevention Regimen For Effectively avoiding Second Strokes) trial — the world’s largest clinical research study for secondary stroke prevention — were presented at the XVII European Stroke Conference in Nice, France. In the study, recurrent stroke event rates for Aggrenox(R) and clopidogrel were similar (9.0% and 8.8%, respectively; HR 1.01, 95% CI 0.92-1.11).

More: continued here

No Comments »

A new, first in class sleep medication is launched, offering hope for thousands of sufferers of insomnia in Europe. Circadin(R), sustained-release melatonin, provides natural sleep by increasing the body’s own level of this naturally occurring hormone throughout the night. (1) Melatonin is the hormone responsible for regulating the circadian rhythm (or sleep cycle) and enabling restorative sleep.

More: continued here

No Comments »

Innovative prism glasses can significantly improve the vision and the daily lives of patients with hemianopia, a condition that blinds half the visual field in both eyes. The peripheral prism glasses, which were invented by Dr. Eli Peli, a Senior Scientist at Schepens Eye Research Institute, were evaluated in the first community-based multi- center trial of such a device, which is published in the May issue of the Archives of Ophthalmology.

More: continued here

No Comments »

Higher incidences of congenital anomalies, including cryptorchidism (undescended testicles) and hypospadias, were found in boys whose mothers had higher serum levels of certain organochlorine compounds, researchers say.

More: continued here

No Comments »

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) announced 12-month interim data from its Phase I/IIa clinical trial of Cethrin, a proprietary recombinant protein that is being investigated for its potential to restore motor and sensory function after spinal cord injury, or SCI. The trial enrolled a total of 48 patients of which 37 have reached the final 12 month follow up evaluation.

More: continued here

No Comments »

Daiichi Sankyo, Inc. announced that data presented at the American Society of Hypertension’s Twenty-Third Annual Scientific Meeting (ASH 2008) in New Orleans demonstrates that a cumulative 45 percent of patients with stage 1 hypertension treated with a regimen of BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) were able to safely and effectively achieve a normotensive blood pressure,

More: continued here

No Comments »

Vicor Technologies, Inc. (OTCBB: VCRT) is pleased to announce positive results of a clinical study conducted by the Company, and accepted for publication in the August 2008 issue of Therapeutics and Clinical Risk Management. The study is titled “Risk Stratification for Arrhythmic Death in an Emergency Department Cohort: a new method of nonlinear PD2i analysis of the ECG.” The study enrolled 918 patients (876 of which completed the study) in six emergency departments.

More: continued here

No Comments »

NicOx S.A. (Eurolist: COX) announced that Merck & Co., Inc. has initiated the first in a series of planned clinical studies, in mild to moderate hypertensive patients, under the companies’ collaborative agreement to develop new nitric oxide-donating antihypertensive agents using NicOx’ proprietary technology.

More: continued here

No Comments »

Virostatics, srl, a privately-held pharmaceutical company focused on the discovery and development of combination therapeutics in HIV/AIDS, virology, and other chronic diseases, announced it has initiated dosing of subjects in its five-arm, dose-ranging, proof of principle study VS411-C201: A randomized double-blind dose-finding multi-centre Phase IIa study with VS411 for HIV-1 infection.

More: continued here

No Comments »

Argos Therapeutics announced the initiation of a Phase 2a proof-of-concept clinical trial to test the efficacy of its AGS-004 therapy in improving immune control of viral replication in HIV-infected adults. AGS-004 is a product of the Company’s Arcelis? technology, a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.

More: continued here

No Comments »